YCBD

cbdMD Inc. (YCBD) | Rumor.io

cbdMD

YCBD

Attention (50-day avg)0%

Attention rank (50-day avg)#2,194

Bullish sentiment (50-day avg)94%

Price to earnings ratio2.04

Market capitalization5.2M

Earnings per share0.23

Dividend yield (TTM)—

Revenue (annual)19.2M

Net income (annual)-2M

Social

What share of all stock conversation is about YCBD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Sep 21

$YCBD's acquisition agreement is expected to close soon, with the deal potentially bringing in $30M in revenue.
The acquisition is a catalyst that could be causing selling pressure on the stock, with some investors experiencing issues with the trading platform Robinhood.
There are concerns about the reliability of Robinhood, with some users reporting hacking incidents and others experiencing issues with exiting their positions.

Generated by AI

Sentiment

Of the messages about YCBD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	90% -4.67	94.57% +7.07	90.89% -3.06
Bearish	—	10% +4.67	5.43% -7.07	9.11% +3.06

Bullish· Sep 18

YCBD's net sales have seen a 61% year-over-year increase, indicating strong growth.
The company has made $30m in revenue per year, which could support further growth and a potential rise in stock price.
A significant acquisition of $6m could potentially lead to a 5X increase in the company's market capitalization, supporting a bullish outlook.

Bearish· Apr 23

$YCBD is predicted to fall to $10.
The current situation sets up $YCBD nicely for a price increase, but the industry's price action is currently a concern.
$YCBD is expected to reach $7.42 or $2 plus, with some predicting a 300% increase.

Generated by AI

Topics

Of the messages about YCBD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	86.79%	2.7%
Technical Analysis	0%	0%	13.21%	1.63%
Analysts	0%	0%	0%	47.39%
Controversies	0%	0%	0%	0.18%
Earnings	0%	0%	0%	0.5%
Macro	0%	0%	0%	47.6%

Announcements· Dec 19

$YCBD closed a $2.25M Series C Preferred private placement, securing fresh capital and momentum.
cbdMD reports its third consecutive year of operating improvement, strengthens its balance sheet, and regains NYSE American Continued Listing Compliance.
The company issued 1,000,000 shares of Series C Convertible Preferred Stock to institutional investors in exchange for $2.25 million in gross proceeds.

Technical Analysis· Dec 17

$YCBD has been consolidating and may break out above $2.40 to continue its upward trend.
The stock has shown accumulation on multiple time frames, with a potential push to $2.00 or $2.40+.
A clean breakout above $2.46 is necessary for further price appreciation, with current volume and price action suggesting a potential continuation.

Generated by AI

Community

Of the messages about YCBD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	39.13%	42.13%	11.35%
Newcomers	100%	60.87%	57.87%	88.65%

Regulars· Dec 19

The regulars are focused on the fact that YCBD has closed a $2.25M Series C Preferred private placement, which provides fresh capital and increases momentum.
YCBD has reported its third consecutive year of operating improvement, strengthened its balance sheet, and regained NYSE American continued listing compliance.
The recent price action has been significant, with $YCBD increasing by +20% after hours, and high trading volumes, with 10.7M shares traded at $1.49 and 6.9M shares traded at $1.57.

Newcomers· Sep 21

Newcomers are excited about a patent news announcement from cell-free regenerative medicine platform CELZ, which is also entering a definitive agreement with CBDMD, Inc. (YCBD).
Many are experiencing issues with Robinhood (RH) and are unable to exit or make trades due to outages, with some speculating that the platform may be hacked.
Some users are speculating about the possibility of a short squeeze in YCBD, with one user suggesting that a large number of hedge funds may be holding short positions that could be affected.

Generated by AI

News

Twinlab Assets Acquired by cbdMD Amid Creditor Assignment

Tipranks Press Release.

26d agotheglobeandmail.com

cbdMD to acquire Twinlab supplement brands for $30M revenue boost

28d agoInvesting.com

cbdMD Inc (YCBD) (Q3 2026) Earnings Call Highlights: Strategic Pivot and Cost Cuts Aim to ...

cbdMD Inc (YCBD) reports 20% revenue growth driven by wholesale and Oasis brand momentum, while implementing aggressive cost reductions to lower breakeven and navigate a shifting regulatory landscape.

1mo agoYahoo Finance

cbdMD Q3 2026 Earnings Call: Complete Transcript

1mo agoBenzinga

Earnings call transcript: cbdMD misses Q3 2026 EPS as shares fall after hours

1mo agoInvesting.com

cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

cbdMD, Inc. (NYSE American: YCBD), one of the nation's leading and most trusted CBD companies and operator of the cbdMD, Bluebird Botanicals, and Paw CBD brands, along with its hemp-derived THC beverage brand Oasis and functional-mushroom brand ATRx Labs, today announced financial results for the third quarter of fiscal year 2026, ended June 30, 2026.

1mo agoYahoo Finance

Also Discussed

Investors talking about YCBD also mention

#	Name	Attention
1	Flash Sports & Media, Inc.UGRO	0%new
2	AMC Robotics CorporationAMCI	0%0
3	SHF Holdings, Inc. Class A Common StockSHFS	0%-0.01
4	Autozi Internet Technology (Global) Ltd. Class AAZI	0%new
5	SMX (Security Matters) Public Limited CompanySMX	0%+0
6	IVP - Inspire Veterinary Partners, Inc.	——
7	Erayak Power Solution Group Inc. Class A Ordinary SharesRAYA	0%0
8	Mawson Infrastructure Group Inc.MIGI	0%0
9	Akanda Corp.AKAN	0%+0
10	IM Cannabis Corp.IMCC	0%+0

cbdMD Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

cbdMD Inc. is a consumer wellness company focused on hemp-derived cannabinoid products and related functional brands. cbdMD offers a broad range of products for human and pet use, including CBD tinctures, gummies, topicals, capsules, softgels, oils, bath products, drink mixes, sleep and calming aids, and hemp-derived Delta-9 THC formulations. Its portfolio includes the cbdMD, Paw CBD, hempMD, cbdMD Botanicals, and ATRx brands, serving customers through e-commerce, wholesale partners, and brick-and-mortar retail channels. The company’s products are positioned across wellness categories such as recovery, mobility, mood, discomfort, cognitive support, and stress management. Based in Charlotte, North Carolina, cbdMD Inc. operates as a specialized brand owner and distributor within the evolving hemp and natural supplements market.

Website

Location

2101 Westinghouse Blvd

Charlotte, NC, 28273

United States

Social

What share of all stock conversation is about YCBD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Sep 21

$YCBD's acquisition agreement is expected to close soon, with the deal potentially bringing in $30M in revenue.
The acquisition is a catalyst that could be causing selling pressure on the stock, with some investors experiencing issues with the trading platform Robinhood.
There are concerns about the reliability of Robinhood, with some users reporting hacking incidents and others experiencing issues with exiting their positions.

Generated by AI

Sentiment

Of the messages about YCBD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	90% -4.67	94.57% +7.07	90.89% -3.06
Bearish	—	10% +4.67	5.43% -7.07	9.11% +3.06

Bullish· Sep 18

YCBD's net sales have seen a 61% year-over-year increase, indicating strong growth.
The company has made $30m in revenue per year, which could support further growth and a potential rise in stock price.
A significant acquisition of $6m could potentially lead to a 5X increase in the company's market capitalization, supporting a bullish outlook.

Bearish· Apr 23

$YCBD is predicted to fall to $10.
The current situation sets up $YCBD nicely for a price increase, but the industry's price action is currently a concern.
$YCBD is expected to reach $7.42 or $2 plus, with some predicting a 300% increase.

Generated by AI

Topics

Of the messages about YCBD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	86.79%	2.7%
Technical Analysis	0%	0%	13.21%	1.63%
Analysts	0%	0%	0%	47.39%
Controversies	0%	0%	0%	0.18%
Earnings	0%	0%	0%	0.5%
Macro	0%	0%	0%	47.6%

Announcements· Dec 19

$YCBD closed a $2.25M Series C Preferred private placement, securing fresh capital and momentum.
cbdMD reports its third consecutive year of operating improvement, strengthens its balance sheet, and regains NYSE American Continued Listing Compliance.
The company issued 1,000,000 shares of Series C Convertible Preferred Stock to institutional investors in exchange for $2.25 million in gross proceeds.

Technical Analysis· Dec 17

$YCBD has been consolidating and may break out above $2.40 to continue its upward trend.
The stock has shown accumulation on multiple time frames, with a potential push to $2.00 or $2.40+.
A clean breakout above $2.46 is necessary for further price appreciation, with current volume and price action suggesting a potential continuation.

Generated by AI

Community

Of the messages about YCBD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	39.13%	42.13%	11.35%
Newcomers	100%	60.87%	57.87%	88.65%

Regulars· Dec 19

The regulars are focused on the fact that YCBD has closed a $2.25M Series C Preferred private placement, which provides fresh capital and increases momentum.
YCBD has reported its third consecutive year of operating improvement, strengthened its balance sheet, and regained NYSE American continued listing compliance.
The recent price action has been significant, with $YCBD increasing by +20% after hours, and high trading volumes, with 10.7M shares traded at $1.49 and 6.9M shares traded at $1.57.

Newcomers· Sep 21

Newcomers are excited about a patent news announcement from cell-free regenerative medicine platform CELZ, which is also entering a definitive agreement with CBDMD, Inc. (YCBD).
Many are experiencing issues with Robinhood (RH) and are unable to exit or make trades due to outages, with some speculating that the platform may be hacked.
Some users are speculating about the possibility of a short squeeze in YCBD, with one user suggesting that a large number of hedge funds may be holding short positions that could be affected.

Generated by AI

cbdMD

Social

Sep 21

Bullish· Sep 18

Bearish· Apr 23

Announcements· Dec 19

Technical Analysis· Dec 17

Regulars· Dec 19

Newcomers· Sep 21

Twinlab Assets Acquired by cbdMD Amid Creditor Assignment

cbdMD to acquire Twinlab supplement brands for $30M revenue boost

cbdMD Inc (YCBD) (Q3 2026) Earnings Call Highlights: Strategic Pivot and Cost Cuts Aim to ...

cbdMD Q3 2026 Earnings Call: Complete Transcript

Earnings call transcript: cbdMD misses Q3 2026 EPS as shares fall after hours

cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

Also Discussed

cbdMD Inc.

Company Information

Location

Social

Sep 21

Bullish· Sep 18

Bearish· Apr 23

Announcements· Dec 19

Technical Analysis· Dec 17

Regulars· Dec 19

Newcomers· Sep 21

Twinlab Assets Acquired by cbdMD Amid Creditor Assignment

cbdMD to acquire Twinlab supplement brands for $30M revenue boost

cbdMD Inc (YCBD) (Q3 2026) Earnings Call Highlights: Strategic Pivot and Cost Cuts Aim to ...

cbdMD Q3 2026 Earnings Call: Complete Transcript

Earnings call transcript: cbdMD misses Q3 2026 EPS as shares fall after hours

cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026

Also Discussed